https://www.selleckchem.com/pr....oducts/ici-118551-ic
After adjustment for age, race, and metastatic stage, patients in Cohort C showed an improvement in OS and CSS compared with Cohort B (HR 0.94 (95% CI 0.91-0.97), p = 0.001; HR 0.89 (95% CI 0.85-0.92), p less then 0.001). Patients with M1c disease had a more pronounced improvement in OS and CSS compared with the other stages. No differences were found between Cohorts B and C. In conclusion, the real-world survival of de novo mPCa remains poor, with a median OS and CSS improvement of only 4 months in the latest years. Obes
Like
Comment
Share
